043 Feasibility, Efficacy and Safety of PDA Stenting With IBS ® in Duct-Dependent Cyanotic CHD

Abstract

PDA (Patent ductus arteriosus) stenting is an acceptant way of temporarily palliating congenital heart diseases (CHD) while waiting surgical repair which incorporates stent removal and often reconstruction of branch pulmonary arteries in 6–12 months. IBS (iron based bioresorbable stent) has recently undergone multicenter clinical trial for coronary artery disease and case reported in stenting PDAs in neonates. The aim is to prospectively evaluate the feasibility, safety and early outcome of this stent (non-drug eluting) in a non-complex PDA morphology. Nine neonates included in this study (CHD with weight >3 kg and age less than 3 months with non-complex PDA anatomy) had PDA IBS stented in the period September 2018 – August 2019.Complex PDAs were excluded. Three monthly follow-up with clinical examination, serum iron and echocardiographic assessment were performed to assess patency of PDA till next surgical intervention/PDA not required as a source of pulmonary blood flow or 9 months post PDA stent. Nine patients underwent PDA IBS stent. Median age and weight at time of intervention were 20.44 days (±5.98) and 3.36 kg (±0.36) respectively. All stents were implanted successfully. Median procedure length 89.30 minutes (±38.52). At least 6 months follow-up. Only one patient (11%) needed earlier reintervention with re-stenting 4months post stent. No stent related mortality /morbidity (one non-cardiac death) Serum iron levels remained normal at all times. PDA shunt noted in all but one at time of planned surgical intervention. IBS stent appears to be feasible, safe and comparable to standard approach from early outcome point of view.